The COVID vaccines have saved approximately 20 million lives globally and produced substantial revenue for pharmaceutical companies. Despite the significant investment in these vaccines, funding for experimental vaccines for various diseases has remained low. The report by the Biotechnology Innovation Organization (BIO) highlighted that only 3.4% of all venture capital raised for biopharma companies in the past decade went towards infectious disease vaccines, totaling $6.5 billion. In contrast, firms developing potential cancer drugs received 38% of venture capital, or $72.6 billion during the same period. The report emphasizes the need for increased investment in experimental vaccines for other diseases.
Source link
Investment in vaccine development is lagging, report finds
